174 related articles for article (PubMed ID: 8477197)
1. Serum erythropoietin and circulating BFU-E in patients with multiple myeloma and anaemia but without renal failure.
Majumdar G; Westwood NB; Bell-Witter C; Muggleston D; Phillips J; Pearson TC
Leuk Lymphoma; 1993 Jan; 9(1-2):173-6. PubMed ID: 8477197
[TBL] [Abstract][Full Text] [Related]
2. [Inadequate erythropoietin production (epo) in patients with multiple myeloma].
Kostova G; Siljanovski N
Prilozi; 2004; 25(1-2):53-66. PubMed ID: 15735535
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of causes for anemia in patients with multiple myeloma].
Rokicka-Piotrowicz M; Paszkowska M; Król M; Król M; Kuratowska Z
Pol Arch Med Wewn; 2000 Dec; 104(6):843-51. PubMed ID: 11424663
[TBL] [Abstract][Full Text] [Related]
4. The secretory erythropoietin response in patients with multiple myeloma and Waldenström's macroglobulinaemia.
Nielsen OJ; Brandt M; Drivsholm A
Scand J Clin Lab Invest; 1990 Nov; 50(7):697-703. PubMed ID: 2127316
[TBL] [Abstract][Full Text] [Related]
5. Circulating haematopoietic progenitors during treatment of renal anaemia with recombinant human erythropoietin.
Göbel V; Hoffmann HG; Müller-Wiefel DE; Braun A; Ludwig R; Schärer K; Debatin KM
Eur J Pediatr; 1994 Jan; 153(1):43-8. PubMed ID: 8313924
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
7. Dose dependent reduction of erythroid progenitor cells and inappropriate erythropoietin response in exposure to lead: new aspects of anaemia induced by lead.
Osterode W; Barnas U; Geissler K
Occup Environ Med; 1999 Feb; 56(2):106-9. PubMed ID: 10448314
[TBL] [Abstract][Full Text] [Related]
8. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells.
Lezaic V; Biljanovic-Paunovic L; Pavlovic-Kentera V; Djukanovic L
Eur J Med Res; 2001 Jan; 6(1):27-32. PubMed ID: 11313188
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of serum erythropoietin levels in patients with multiple myeloma].
Takagi M; Miyamoto Y; Kosaka M; Saito S
Rinsho Ketsueki; 1992 Sep; 33(9):1151-7. PubMed ID: 1433935
[TBL] [Abstract][Full Text] [Related]
11. Current and potential applications for erythropoietin.
Pedrazzini A
Acta Haematol; 1992; 87 Suppl 1():2-3. PubMed ID: 1574962
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness to recombinant erythropoietin therapy in end-stage renal disease. An analysis of the predictive value of several biological measurements, including circulating erythroid progenitors.
Corazza F; Bergmann P; Dratwa M; Guns M; Fondu P
Nephrol Dial Transplant; 1992; 7(4):311-7. PubMed ID: 1317521
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin and the anemia of multiple myeloma.
Barlogie B; Beck T
Stem Cells; 1993 Mar; 11(2):88-94. PubMed ID: 8457789
[TBL] [Abstract][Full Text] [Related]
15. End-stage renal disease following polycythemia vera: in vitro and in vivo response of erythroid progenitors to erythropoietin and effects of sera on normal erythropoiesis.
Shih LY; Huang JY
Nephron; 1998; 79(2):142-7. PubMed ID: 9647492
[TBL] [Abstract][Full Text] [Related]
16. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
17. In vitro studies of erythropoietin-dependent regulation of erythropoiesis in myelodysplastic syndromes.
Merchav S; Nielsen OJ; Rosenbaum H; Sharon R; Brenner B; Tatarsky I; Scigalla P; Wieczorek L
Leukemia; 1990 Nov; 4(11):771-4. PubMed ID: 2232891
[TBL] [Abstract][Full Text] [Related]
18. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
19. Circadian rhythm of serum erythropoietin in multiple myeloma.
Pasqualetti P; Collacciani A; Casale R
Am J Hematol; 1996 Sep; 53(1):40-2. PubMed ID: 8813096
[TBL] [Abstract][Full Text] [Related]
20. Circulating burst-forming unit-erythroid (BFU-E) colonies as an early marker to measure the recombinant human erythropoietin response in peritoneal dialysis patients.
Castro MA; Fernandez de Castro M; Selgas R; Fernandez-Reyes MJ; Bajo MA; Jimenez C; Del Peso G; Dapena F; de Alvaro F
Adv Perit Dial; 1996; 12():66-70. PubMed ID: 8865876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
